NCIt definition : A fully human IgG1 monoclonal antibody directed against human vascular endothelial
growth factor receptor 1 (VEGFR-1/FLT-1) with potential antiangiogenesis and antineoplastic
activities. Icrucumab specifically binds to and inhibits the activity of VEGFR-1,
which may prevent the activation of downstream signaling pathways and so inhibit tumor
angiogenesis; the subsequent reduction in tumor nutrient supply may inhibit tumor
cell proliferation. Tumor cell overexpression of VEGFR-1 may be associated with tumor
angiogenesis and tumor cell proliferation and invasion; VEGFR-1 may modulate VEGFR-2
signaling.;